Home Tags Seattle Genetics

Tag: Seattle Genetics

Potential Accelerated Approval for Enfortumab Vedotin in Combination with Pembrolizumab as...

Updated data from the phase Ib/II multicohort EV-103 trial (NCT03288545; also known as KEYNOTE-869) of enfortumab vedotin* (Padcev™; Seattle Genetics/Astellas Pharma) in combination with...

Five Prime Therapeutics Licenses Antibodies to Seattle Genetics

One day after Bristol-Myers Squibb and Five Prime Therapeutics announced that a randomized Phase II study testing the combination of cabiralizumab and nivolumab (Opdivo®),...

European Regulators Approve Polatuzumab Vedotin, Triggering Milestone Payment for Seattle Genetics

The European Commission's conditional marketing authorization of polatuzumab vedotin (Polivy®; Genentech/Roche) earlier this week triggered a milestone payment which Seattle Genetics will receive from...

Accelerated Approval for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial...

The U.S. Food and Drug Administration (FDA) granted accelerated approval to enfortumab vedotin-ejfv (Padcev™; Astellas Pharma / Seattle Genetics)* for the treatment of adult...
Featured Image: Annual Congress of ESMO 2018. Courtesy: © 2018 European Society for Medical Oncology. Used with permission.

ESMO 2019: Seattle Genetics to Present Initial Data from a Phase...

Less than a week before the start of the annual meeting of the European Society for Medical Oncology (ESMO), to be held September 27...
Astellas Pharma, Exhibition booth during ASCO 2019, held May 31 – June 4, 2019 in Chicago, Ill.| Courtsey: Emila Duaerte / Sunvalley Communication

U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application...

The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for the investigational agent enfortumab vedotin, also known as ASG-22CE,...
Seattle Genetics

5 Things You Need To Know This Week About ADCs –...

This is the second article in my series of updates about the goings on in the world of ADCs over the last two weeks....
Exhibition booth Seattle Genetics - ASCO 2019 | Courtsey: Emila Duaerte / Sunvalley Communication

Phase III Clinical Trials of Brentuximab Vedotin Continue to Demonstrate Superior...

Additional, updated, analyses of results from ECHELON-1 and ECHELON-2, the frontline phase III trials of brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda), an antibody-drug conjugate or...

Interim Results from Ongoing Studies of Brentuximab Vedotin + Nivolumab in...

Multiple presentations evaluating brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda*) across a broad range of Hodgkin lymphoma (HL) settings were presented at the 11th International Symposium...

PharmaMar and Seattle Genetics Sign Licensing Agreement for Fully Synthetic Marine-derived...

Earlier this week PharmaMar, an Madrid-based biopharmaceutical company developing innovative marine-derived anticancer drugs, signed an exclusive agreement with Seattle Genetics in which the company...